CalciMedica, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALC research report →
Companywww.calcimedica.com
CalciMedica, Inc. , a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.
- CEO
- A. Rachel Leheny
- IPO
- 2023
- Employees
- 14
- HQ
- La Jolla, CA, US
Price Chart
Valuation
- Market Cap
- $10.19M
- P/E
- -0.50
- P/S
- 0.00
- P/B
- -8.77
- EV/EBITDA
- -0.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 4092.98%
- ROIC
- -674.61%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-29,562,000 · -115.78%
- EPS
- $-1.97 · -61.48%
- Op Income
- $-23,121,000
- FCF YoY
- -0.25%
Performance & Tape
- 52W High
- $7.20
- 52W Low
- $0.46
- 50D MA
- $0.64
- 200D MA
- $2.58
- Beta
- 0.82
- Avg Volume
- 284.12K
Get TickerSpark's AI analysis on CALC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 5, 25 | Bardin Stephen | other | 67,728 |
| Apr 5, 25 | Hebbar Sudarshan | other | 91,173 |
| Apr 5, 25 | Roberts Eric W | other | 83,358 |
| Apr 5, 25 | Dunn Michael J. | other | 65,124 |
| Apr 5, 25 | Stauderman Kenneth A. | other | 65,124 |
| Apr 5, 25 | Leheny A. Rachel | other | 148,482 |
| Oct 13, 25 | Glicklich Alan | other | 937 |
| Sep 18, 25 | Roberts Eric W | buy | 2,500 |
| Sep 15, 25 | Roberts Eric W | buy | 3,400 |
| Sep 12, 25 | Roberts Eric W | buy | 5,000 |
Our CALC Coverage
We haven't published any research on CALC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CALC Report →